Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corp    CVS

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Exclusive: Ernst, audit clients cut lobbying ties-records

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/04/2012 | 07:11am CET

Ernst & Young's lobbying unit is no longer listed as a lobbyist for three major U.S. companies, all of whom were 2011 audit clients of the accounting giant. The deregistration follows questions raised by two U.S. senators in March about whether the dual relationships crossed auditor independence boundaries.

Documents filed last month with Congress showed that Washington Council Ernst & Young, the E&Y unit, was no longer registered as doing lobbying work for Amgen Inc (>> Amgen, Inc.), CVS Caremark Corp (>> CVS Caremark Corporation) and Verizon Communications Inc (>> Verizon Communications Inc.).

A lobbying-contract termination was also filed on March 31 for a fourth company, Nomura Holdings Inc (>> Nomura Holdings Inc.), which, according to securities filings, uses an E&Y affiliate for auditing services. E&Y had provided lobbying services to Nomura since June 2011, according papers on file with Congress.

Auditors that review corporations' books every year must follow rules limiting other ties with audit clients. The rules - meant to prevent auditors from getting too cozy with audit clients - were substantially beefed up a decade ago after a rash of accounting scandals at Enron Corp. and other companies.

An Ernst & Young spokesman declined to comment on the discontinued lobbying relationships. Officials with Nomura, Verizon and CVS declined to comment. Amgen officials could not immediately be reached for comment.

The chief accountant for the U.S. Securities and Exchange Commission, James Kroeker, speaking at a financial reporting conference at Baruch College in New York on Thursday, said SEC rules state an auditor should not act in an advocacy role for a company it audits and lobbying would be inconsistent with that.

Kroeker did not mention any audit firms by name.

He said: "If you think about lobbying in the traditional sense, you would say, 'wouldn't somebody that's lobbying be placing themselves in a position to be an advocate?'"

Asked whether the SEC was looking into E&Y's lobbying activities, an official in the agency's enforcement division declined to comment because its investigations are not public.

"We are aware of it and we are cognizant of what the rules are," said Howard Scheck, chief accountant of the SEC's division of enforcement, on the sidelines of Thursday's conference.

"If there's a violation that we find, we'll certainly do something about that," he said, without referring to E&Y.

Reuters reported in March that Washington Council Ernst & Young had been hired as a lobbyist for a number of E&Y's audit clients, prompting two lawmakers to demand closer scrutiny.

Democratic senators Carl Levin and Jack Reed both expressed concerns at the time and urged the SEC to look into the matter. On Thursday, Reed's office did not immediately respond to inquiries seeking comment. Levin's office declined to comment.

Verizon had a particularly long relationship with E&Y's lobbyists, who helped the telecommunications company with tax issues beginning in September 2001. The two other lobbying relationships were more recent, dating to February in the case of Amgen and September in the case of CVS Caremark. Both contracts were connected to corporate tax debates. The three U.S. terminations were all effective March 31 and Nomura's termination was filed the same day.

The E&Y spokesman referred Reuters to its earlier statement that Washington Council's work complied with independence rules.

The work was approved by clients' audit committees and it was limited to tax-related issues, E&Y spokesman Charles Perkins said when Reuters reported on the issue in March.

Washington Council did not solicit votes on legislation for E&Y audit clients, Perkins said.

The Public Company Accounting Oversight Board, the watchdog for U.S. auditors, is looking to shore up independence rules after finding numerous instances in which auditors did not dig deeply enough to challenge clients' financial numbers.

The SEC's Kroeker said he was encouraged to see the board tackling the subject.

"Independence is really the bedrock, the foundation of the value that's provided by a third-party audit," he said.

(Reporting by Dena Aubin and David Ingram; Additional reporting by Kim Dixon; Editing by Kevin Drawbaugh and Matt Driskill)

By David Ingram and Dena Aubin

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORP
01/14 CVS HEALTH : Canada Pension Plan Investment Board Has $249,866,000 Position in C..
01/14 CVS HEALTH : targets EpiPen with cheaper, generic version
01/13 CVS HEALTH : unveils generic competitor to EpiPen for one-sixth the price
01/13 CVS HEALTH : More Mylan misery
01/13 CVS HEALTH : Vende CVS versión genérica de Epipen a un sexto de su precio
01/12 CVS HEALTH : generic competitor to EpiPen, sold at a 6th the price
01/12 CVS HEALTH : puts out generic competitor to EpiPen at a 6th the price
01/12 CVS HEALTH : Flu Shots Available at CVS Pharmacy Locations in Washington
01/12 CVS HEALTH : Supporting Those Who Care for Our Aging Population
01/09 CVS HEALTH : Carjacking victim, shot nine times, suing CVS
More news
Sector news : Drug Retailers - NEC
03:03aDJMCKESSON : to Pay $150 Million for Failing to Report 'Suspicious' Drug Orders --..
01:47aDJMCKESSON : to Pay $150 Million for Failing to Report 'Suspicious' Drug Orders
01/11DJWalgreens to Offer FedEx Dropoff and Pickup at Walgreens Locations Nationwide
01/05 U.S. loses bid to overturn AmEx antitrust decision
01/05DJWALGREENS BOOTS CEO : No Plan B for Rite Aid Merger--Update
More sector news : Drug Retailers - NEC
News from SeekingAlpha
01/17 DGI FOR THE DIY : 2016 Portfolio Review
01/17 Impax Laboratories Stock To Rise On New Catalyst
01/16 Portfolio Update - CVS Health Corp. Purchased
01/16 CVS HEALTH : Strong Yield With A Catalyst
01/16 9 Dividend Companies With Lower Share Prices
Advertisement
Financials ($)
Sales 2016 178 057 M
EBIT 2016 10 773 M
Net income 2016 5 672 M
Debt 2016 24 647 M
Yield 2016 1,96%
P/E ratio 2016 16,47
P/E ratio 2017 15,67
EV / Sales 2016 0,64x
EV / Sales 2017 0,61x
Capitalization 89 496 M
More Financials
Chart CVS HEALTH CORP
Duration : Period :
CVS Health Corp Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Full-screen chart
Technical analysis trends CVS HEALTH CORP
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 88,0 $
Spread / Average Target 4,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Stephen J. Gold Chief Information Officer & Executive Vice Preside
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH CORP6.35%89 496
WALGREENS BOOTS ALLIAN..1.76%90 908
EXPRESS SCRIPTS HOLDIN..6.35%45 112
MCKESSON CORPORATION5.68%33 558
CARDINAL HEALTH INC4.46%24 062
AMERISOURCEBERGEN CORP..9.98%18 926
More Results